234 related articles for article (PubMed ID: 36290849)
1. Precision Oncology in Canada: Converting Vision to Reality with Lessons from International Programs.
Liu G; Cheung WY; Feilotter H; Manthorne J; Stockley T; Yeung M; Renouf DJ
Curr Oncol; 2022 Sep; 29(10):7257-7271. PubMed ID: 36290849
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Challenges and opportunities in building a health economic framework for personalized medicine in oncology.
Aguiar PN; Matsas S; Dienstmann R; Ferreira CG
Per Med; 2023 Sep; 20(5):453-460. PubMed ID: 37602420
[TBL] [Abstract][Full Text] [Related]
4. Real-world data for precision cancer medicine-A European perspective.
Christopoulos P; Schlenk R; Kazdal D; Blasi M; Lennerz J; Shah R; Budczies J; Malek N; Fröhling S; Rosenquist R; Schirmacher P; Bozorgmehr F; Kuon J; Reck M; Thomas M; Stenzinger A
Genes Chromosomes Cancer; 2023 Sep; 62(9):557-563. PubMed ID: 36852573
[TBL] [Abstract][Full Text] [Related]
5. Access and quality of biomarker testing for precision oncology in Europe.
Normanno N; Apostolidis K; Wolf A; Al Dieri R; Deans Z; Fairley J; Maas J; Martinez A; Moch H; Nielsen S; Pilz T; Rouleau E; Patton S; Williams V
Eur J Cancer; 2022 Nov; 176():70-77. PubMed ID: 36194905
[TBL] [Abstract][Full Text] [Related]
6. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany.
Stenzinger A; Edsjö A; Ploeger C; Friedman M; Fröhling S; Wirta V; Seufferlein T; Botling J; Duyster J; Akhras M; Thimme R; Fioretos T; Bitzer M; Cavelier L; Schirmacher P; Malek N; Rosenquist R;
Semin Cancer Biol; 2022 Sep; 84():242-254. PubMed ID: 34033893
[TBL] [Abstract][Full Text] [Related]
7. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
8. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
9. The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group.
Chan KKW; Cheung MC; Regier DA; Hay A; Louie AV; Cheung WY; Tarride JE; Udayakumar S; Mittmann N
Curr Oncol; 2021 Sep; 28(5):3649-3658. PubMed ID: 34590616
[TBL] [Abstract][Full Text] [Related]
10. A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.
Regier DA; Pollard S; McPhail M; Bubela T; Hanna TP; Ho C; Lim HJ; Chan K; Peacock SJ; Weymann D
NPJ Precis Oncol; 2022 Oct; 6(1):76. PubMed ID: 36284134
[TBL] [Abstract][Full Text] [Related]
11. THE FUTURE OF MEDICINE, healthcare innovation through precision medicine: policy case study of Qatar.
Qoronfleh MW; Chouchane L; Mifsud B; Al Emadi M; Ismail S
Life Sci Soc Policy; 2020 Nov; 16(1):12. PubMed ID: 33129349
[TBL] [Abstract][Full Text] [Related]
12. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.
Normanno N; Apostolidis K; de Lorenzo F; Beer PA; Henderson R; Sullivan R; Biankin AV; Horgan D; Lawler M
Semin Cancer Biol; 2022 Sep; 84():293-301. PubMed ID: 34389490
[TBL] [Abstract][Full Text] [Related]
13. An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry.
Le Tourneau C; Perret C; Hackshaw A; Blay JY; Nabholz C; Geissler J; Do T; von Meyenn M; Dienstmann R
JCO Precis Oncol; 2022 Jul; 6():e2200019. PubMed ID: 35939770
[TBL] [Abstract][Full Text] [Related]
14. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
[TBL] [Abstract][Full Text] [Related]
15. Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.
Siebert U; Jahn B; Rochau U; Schnell-Inderst P; Kisser A; Hunger T; Sroczynski G; Mühlberger N; Willenbacher W; Schnaiter S; Endel G; Huber L; Gastl G;
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):330-40. PubMed ID: 26354133
[TBL] [Abstract][Full Text] [Related]
16. Future Role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory Perspective.
Husereau D; Bombard Y; Stockley T; Carter M; Davey S; Lemaire D; Nohr E; Park P; Spatz A; Williams C; Pollett A; Lo B; Yip S; El Hallani S; Feilotter H
Curr Oncol; 2023 Oct; 30(11):9660-9669. PubMed ID: 37999120
[TBL] [Abstract][Full Text] [Related]
17. Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP).
Gargallo P; Bautista F; Juan-Ribelles A; Izquierdo E; Soriano A; de Rojas T; Escudero A; Lavarino C; Solano P; Hladun R; Rubio-San-Simón A; Martínez-Romera I; Calabria I; Olaciregui NG; Castañeda-Heredia A; de Álava E; Pérez-Martínez A; Astigarraga I; Patiño-García A; Alonso J; Fernández-Teijeiro A; Cañete A; Moreno L
Clin Transl Oncol; 2022 May; 24(5):809-815. PubMed ID: 35152364
[TBL] [Abstract][Full Text] [Related]
18. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
Tsimberidou AM; Ringborg U; Schilsky RL
Am Soc Clin Oncol Educ Book; 2013; ():118-25. PubMed ID: 23714475
[TBL] [Abstract][Full Text] [Related]
19. Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies.
Gaultney JG; Bouvy JC; Chapman RH; Upton AJ; Kowal S; Bokemeyer C; Solà-Morales O; Wolf J; Briggs AH
Appl Health Econ Health Policy; 2021 Sep; 19(5):625-634. PubMed ID: 34028672
[TBL] [Abstract][Full Text] [Related]
20. Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens.
Radu P; Kumar G; Cole A; Fameli A; Guthrie M; Annemans L; Geissler J; Italiano A; O'Rourke B; Xoxi E; Steuten L
Oncologist; 2024 Jun; 29(6):465-472. PubMed ID: 38630538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
